Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anebulo PharmaceuticalsANEB 35 Cash Ratio is 6.08 as of Dec. 2025, which is 49% below its 10-year median of 11.90. GuruFocus rates ANEB with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 1,384 Biotechnology companies, Anebulo Pharmaceuticals ranks better than 68.28% on this metric.
Anebulo Pharmaceuticals has a Cash Ratio of 6.08. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Anebulo Pharmaceuticals's Cash Ratio or its related term are showing as below:
ANEB'
s Cash Ratio Range Over the Past 10 Years
Min: 2.47 Med: 11.9 Max: 360.18
Current: 6.08
During the past 6 years, Anebulo Pharmaceuticals's highest Cash Ratio was 360.18. The lowest was 2.47. And the median was 11.90.
ANEB's Cash Ratio is ranked better than 68.28% of 1384
companies
in the Biotechnology industry
Industry Median: 2.93
vs ANEB: 6.08
Anebulo Pharmaceuticals (OTCPK:ANEB) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Anebulo Pharmaceuticals Cash Ratio Related Terms
Anebulo Pharmaceuticals Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Anebulo Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anebulo Pharmaceuticals Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Anebulo Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anebulo Pharmaceuticals (ANEB) has a Cash Ratio of 6.08 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Anebulo Pharmaceuticals and its competitors. This is 49% below median its historical median of 11.90. Over the past decade, Anebulo Pharmaceuticals' Cash Ratio has ranged from 2.47 to 360.18. According to the industry distribution chart, Anebulo Pharmaceuticals ranks #439 out of 1384 companies in the Biotechnology industry, placing it in the top 31.7%.
Is Anebulo Pharmaceuticals' Cash Ratio too high?
Anebulo Pharmaceuticals' current Cash Ratio of 6.08 is 49% below median its 10-year median of 11.90. Over the past 10 years, this metric has ranged from a low of 2.47 to a high of 360.18. The Biotechnology industry median Cash Ratio is 2.93. Anebulo Pharmaceuticals' value of 6.08 is 107.5% above this industry median. Based on the distribution chart, Anebulo Pharmaceuticals ranks #439 out of 1384 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Anebulo Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Anebulo Pharmaceuticals' Cash Ratio compare to PHIO and COCP?
According to the Biotechnology industry distribution chart, Anebulo Pharmaceuticals ranks #439 out of 1384 companies for Cash Ratio. This puts Anebulo Pharmaceuticals in the upper half of its industry. The industry median Cash Ratio is 2.93. Anebulo Pharmaceuticals' value of 6.08 is 107.5% above this benchmark. Historically, Anebulo Pharmaceuticals' own Cash Ratio has ranged from 2.47 to 360.18 over the past decade. While the company's 10-year median is 11.90 vs. the industry median of 2.93, Anebulo Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anebulo Pharmaceuticals's current Cash Ratio of 6.08 is 107.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Anebulo Pharmaceuticals and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anebulo Pharmaceuticals's current Cash Ratio is 6.08, which is 49% below median its own 10-year median of 11.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anebulo Pharmaceuticals stock overvalued right now?
Anebulo Pharmaceuticals (ANEB) has a current Cash Ratio of 6.08. The current Cash Ratio is 6.08, which is 49% below median its 10-year median of 11.90 and 107.5% above the Biotechnology industry median of 2.93. Anebulo Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Anebulo Pharmaceuticals (ANEB), the current Cash Ratio is 6.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
35GF Score
Get the complete analysis for ANEB
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANEB has been successfully added to your 
